Cancer patients may experience delayed skin effects of anti-PD-1 therapy

July 18, 2018

PHILADELPHIA - Cancer patients receiving anti-PD-1 therapies who develop lesions, eczema, psoriasis, or other forms of auto-immune diseases affecting the skin may experience those adverse reactions on a delay - sometimes even after treatment has concluded. In a study that provides guidance for physicians and has implications for patient counseling - dermatologists in the Perelman School of Medicine at the University of Pennsylvania found patients developed skin disease a median of four months after starting treatment, though in one case, the effects were not observed until more than three years later. They published their findings in JAMA Dermatology today.

PD-1 is a checkpoint protein on T cells, which are crucial to the immune system's ability to fight off disease. Anti-PD-1 immunotherapies like pembrolizumab (Keytruda) or nivolumab (Opdivo) turn off the checkpoint, leaving T cells free to do their job. The approach has become standard of care in multiple cancers, including lung cancer and melanoma. About 40 percent of patients treated with these therapies will develop auto-immune diseases affecting the skin, which can include eczema, psoriasis, and lupus-like reactions, among others.

"The impact of these treatments on the skin is well documented, but there has been relatively little focus on the timing of these adverse events - a crucial point that can both inform doctors on what to watch for and aid them as they counsel patients on what to expect," said the study's senior author Emily Y. Chu, MD, PhD, an assistant professor of Dermatology. Leo L. Wang, BA, MS, a medical student, is the study's lead author.

Researchers compiled data on 17 patients seen at Penn between 2014 and 2018 - all of whom had biopsies of their skin reactions. Twelve had melanoma, while three had squamous cell carcinoma and two had renal cell carcinoma. All patients had metastatic disease.

The study showed 12 of the 17 patients experienced skin disease three months or later after beginning treatment with pembrolizumab or nivolumab. The soonest a reaction developed was two weeks, while the longest was 38 months. In five patients, the reactions attributed to the anti-PD-1 therapy developed after the patients were no longer receiving the drug.

"While we can't definitively say that the skin reactions occurring after treatment was discontinued are linked to the therapies, the reactions we observed are typical of those frequently attributed to anti-PD-1 drugs," Chu said. "We also know that tumor responses are durable even after treatment stops, which is further evidence that skin reactions may also develop during this time."

Chu noted that all of the patients in this study were referred to dermatology by their oncologists. With more oncologists dealing with these common reactions, these symptoms are often addressed during the normal course of treatment, meaning dermatology tends to only see the more severe cases, Chu said.

"Dermatologists need to be aware that these immunotherapies can cause skin reactions with a delayed onset," Chu said. "Patients are living longer, and we need to be prepared to address the long-term effects of the treatments that make that possible."
-end-
Other Penn authors include Zelma C. Chiesa Fuxench, MD, MSCE, Suzanne McGettigan, MSN, Lynn Schuchter, MD, Tara C. Mitchell, MD, and Michael E. Ming, MD, MSCE.

one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751.

Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.

Penn Medicine is committed to improving l

ives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided more than $500 million to benefit our community.

University of Pennsylvania School of Medicine

Related Psoriasis Articles from Brightsurf:

Most psoriasis patients taking immunosuppressants survive COVID-19
Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19.

Getting under the skin of psoriasis
Psoriasis afflicts millions of people worldwide, but treatments are limited to small molecules like steroids, which can cause skin thinning and lose their effectiveness over time.

Psoriasis patients' mental health is more than skin-deep
A new study from Umeå University, Sweden, shows that other somatic diseases have even more impact on patients' mental health than their skin symptoms, highlighting the importance of holistic patient care.

Psoriasis: Towards a novel therapeutic approach
Researchers at the Université libre de Bruxelles (ULB) and the Department of Dermatology of the Erasme hospital uncover the importance of VEGFA signaling in the epidermis to mediate psoriasis development.

Insights into psoriasis suggest a new treatment target
Investigators from Brigham and Women's Hospital and the Harvard Stem Cell Institute have uncovered a novel pathway that may explain why skin thickens in psoriasis and suggests new strategies for developing therapies for the condition.

Psoriasis onset determines if psoriatic arthritis patients develop arthritis or psoriasis first
In a new study presented at the 2019 ACR/ARP Annual Meeting, researchers found the age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis.

Study: Some biologic treatments for psoriasis may be safer for patients
In the largest study of its kind, Erica D. Dommasch, M.D., M.P.H., a dermatologist in the Department of Dermatology at BIDMC, and colleagues found a decreased risk of infection in patients with psoriasis using some of the newer, more targeted medications compared to those taking methotrexate, a drug widely used since the 1960s as a first line treatment for moderate-to-severe psoriasis.

Higher weight increases risk of psoriasis
The higher a person's BMI, the greater the chance of getting psoriasis.

Lipid that aids normal skin turnover may help psoriasis
Topical application of the lipid phosphatidylglycerol, or PG, on a mouse model of psoriasis reduced inflammation as well as characteristic, raised skin lesions, they report in the Journal of Investigative Dermatology.

New insight into the mechanism of the drug against sclerosis and psoriasis
A multidisciplinary research team at Aarhus University has provided fundamental new insight into the mechanism of the medical drug dimethyl fumarate, which is the active component of important treatments for multiple sclerosis and psoriasis.

Read More: Psoriasis News and Psoriasis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.